Lilly’s Olumiant Could Get Blood Clot Redemption With EUA For COVID
Executive Summary
When the US FDA approved Olumiant (baricitinib) for RA, it insisted on a lower dose because of fears of blood clots. Now that an NIH trial has shown that the product plus Gilead’s Veklury (remdesivir) provided a statistically significant reduction in time to recovery versus remdesivir alone for hospitalized COVID patients, Olumaint may get an emergency use authorization from FDA to treat a condition that itself causes blood clots. That doesn't mean the black box is going away; it's just a reminder that there is as much magic and mystery to medicine sometimes as there is science.
You may also be interested in...
Lilly Gets Second EUA, For Baricitinib In COVID-19 Patients
Weeks after FDA authorized emergency use of its antibody bamlanivimab, Lilly’s RA drug Olumiant can be used to shorten recovery time for hospitalized COVID-19 patients in the US. Authorizations are being pursued elsewhere as well.
EU Firsts Beckon For Olumiant In Dermatitis & Orfadin For AKU
The European Medicine Agency has recommended extending the therapeutic indication of a raft of drugs that are already authorized in the EU.
Preventing Missing Data Among Concerns In US FDA’s Guidance On COVID-19 Symptom Assessment
Investigators should plan to find the vital status of discontinued patients, guidances states. Participants need frequent reminders to complete PRO instruments, agency recommends.